589 related articles for article (PubMed ID: 16200237)
21. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis.
Rost D; Rudolph G; Kloeters-Plachky P; Stiehl A
Hepatology; 2004 Sep; 40(3):693-8. PubMed ID: 15349909
[TBL] [Abstract][Full Text] [Related]
22. Primary biliary cirrhosis and bile acids.
Corpechot C
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S13-20. PubMed ID: 23141888
[TBL] [Abstract][Full Text] [Related]
23. Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells.
Arenas F; Hervias I; Uriz M; Joplin R; Prieto J; Medina JF
J Clin Invest; 2008 Feb; 118(2):695-709. PubMed ID: 18188457
[TBL] [Abstract][Full Text] [Related]
24. Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease.
O'Brien SM; Campbell GR; Burke AF; Maguire OC; Rowlands BJ; FitzGerald MX; Hegarty JE
Eur J Gastroenterol Hepatol; 1996 May; 8(5):477-83. PubMed ID: 8804877
[TBL] [Abstract][Full Text] [Related]
25. Management of cholestatic disease in 2017.
de Vries E; Beuers U
Liver Int; 2017 Jan; 37 Suppl 1():123-129. PubMed ID: 28052628
[TBL] [Abstract][Full Text] [Related]
26. Long-term response of primary biliary cirrhosis (stage I) to therapy with ursodeoxycholic acid.
Tromm A; May B; Klein CG; Klein R; Fisseler-Eckhoff A; Griga T
Hepatogastroenterology; 2005; 52(63):753-6. PubMed ID: 15966198
[TBL] [Abstract][Full Text] [Related]
27. Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases.
Festi D; Montagnani M; Azzaroli F; Lodato F; Mazzella G; Roda A; Di Biase AR; Roda E; Simoni P; Colecchia A
Curr Clin Pharmacol; 2007 May; 2(2):155-77. PubMed ID: 18690863
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic approaches for hepatobiliary disorders with ursodeoxycholic acid and bile-acid derivatives.
Serfaty L; Poupon R
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S1. PubMed ID: 23141887
[No Abstract] [Full Text] [Related]
29. Drug Therapies for Chronic Cholestatic Liver Diseases.
Wagner M; Fickert P
Annu Rev Pharmacol Toxicol; 2020 Jan; 60():503-527. PubMed ID: 31506007
[TBL] [Abstract][Full Text] [Related]
30. Primary sclerosing cholangitis.
Zein CO; Lindor KD
Semin Gastrointest Dis; 2001 Apr; 12(2):103-12. PubMed ID: 11352117
[TBL] [Abstract][Full Text] [Related]
31. Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents.
Silveira MG; Lindor KD
Clin Liver Dis; 2008 May; 12(2):425-43; x-xi. PubMed ID: 18456189
[TBL] [Abstract][Full Text] [Related]
32. Choleretic effects of ursodeoxycholic acid on experimentally-induced intrahepatic cholestasis.
Mizoguchi Y; Miyajima K; Kioka K; Seki S; Kobayashi K; Morisawa S
Osaka City Med J; 1989 Nov; 35(2):83-91. PubMed ID: 2628845
[TBL] [Abstract][Full Text] [Related]
33. [Cholestatic liver diseases].
Reichel C; Meier-Abt PJ
Ther Umsch; 1997 Nov; 54(11):639-44. PubMed ID: 9454366
[TBL] [Abstract][Full Text] [Related]
34. Pathogenesis of cholestatic liver disease and therapeutic approaches.
Hirschfield GM; Heathcote EJ; Gershwin ME
Gastroenterology; 2010 Nov; 139(5):1481-96. PubMed ID: 20849855
[TBL] [Abstract][Full Text] [Related]
35. [Treatment of cholestatic liver diseases].
Karvonen AL
Duodecim; 2003; 119(6):533-9. PubMed ID: 12708340
[No Abstract] [Full Text] [Related]
36. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy.
Färkkilä M; Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Niemelä O
Liver Int; 2008 Jul; 28(6):787-97. PubMed ID: 18397236
[TBL] [Abstract][Full Text] [Related]
37. [Efficacy of combined administration of ursodeoxycholic acid and hepthral in the treatment of primary biliary cirrhosis].
Avezov SA; Mansurov FKh
Klin Med (Mosk); 2004; 82(3):55-8. PubMed ID: 15114777
[TBL] [Abstract][Full Text] [Related]
38. Effects of ursodeoxycholic acid and chenodeoxycholic acid on human hepatocytes in primary culture.
Hillaire S; Ballet F; Franco D; Setchell KD; Poupon R
Hepatology; 1995 Jul; 22(1):82-7. PubMed ID: 7601437
[TBL] [Abstract][Full Text] [Related]
39. [Ursodeoxycholic acid in the treatment of chronic cholestatic liver disease. Documented delay in disease progress inspires hope].
Olsson R
Lakartidningen; 2002 Mar; 99(12):1325-30. PubMed ID: 11998165
[TBL] [Abstract][Full Text] [Related]
40. Safe use of ursodeoxycholic acid in a breast-feeding patient with primary biliary cirrhosis.
Vítek L; Zelenková M; Brůha R
Dig Liver Dis; 2010 Dec; 42(12):911-2. PubMed ID: 20619755
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
